Potential of DNA-mediated vaccination for equine herpesvirus 1.

The research studies the potential of DNA-mediated vaccination as a protective measure against equine herpesvirus 1 (EHV-1) disease.

Study Design and Procedure

• The investigation of the DNA-mediated vaccination for EHV-1 was conducted on a murine (mouse) model of EHV-1 respiratory infection.
• The process started with an intramuscular injection into the mice of DNA encoding the EHV-1 envelope glycoprotein D (gD). The gD DNA was prepared in a mammalian expression vector for efficacy.
• The scientists closely observed the immune response of the mice, examining the presence of specific antibodies and their progression from 2 to 23 weeks post-injection.

Notable Findings

• The results showed that the immune response was proportionate to the dose of DNA injected. A second injection significantly escalated the antibody response.
• Mice injected with EHV-1 gD DNA developed neutralising antibodies, pointing to a successful immune response due to the vaccination. The surge of IgG2a antibodies after the DNA injection suggested the initiation of a type 1 helper T-cell (Th1) response.
• When subjected to an intranasal challenge with EHV-1, mice immunised with 50 micrograms of EHV-1 gD DNA were able to clear the virus from lung tissue more swiftly and exhibited less lung damage compared to non-immunised mice.

Conclusion

• The data collected from the study support the assertion that DNA-mediated immunisation could be an effective vaccination strategy against EHV-1, evidenced by the improved immune response in the mice ad the reduced lung damage witnessed. More studies would however be required to validate this finding.